A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 141, Issue 7, Pages 1469-1477
Publisher
Wiley
Online
2017-06-20
DOI
10.1002/ijc.30841
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab
- (2016) Ze-xue Zhao et al. Orthopaedic Surgery
- Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
- (2015) J Guo et al. BRITISH JOURNAL OF CANCER
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
- (2015) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
- Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group
- (2015) Cindy L. Schwartz et al. PEDIATRIC BLOOD & CANCER
- Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
- (2014) D. C. Turner et al. CLINICAL CANCER RESEARCH
- Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice
- (2013) Valery F. Scharf et al. AMERICAN JOURNAL OF VETERINARY RESEARCH
- Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
- (2013) Xiao-Wei Yu et al. TUMOR BIOLOGY
- VEGF Inhibition, Hypertension, and Renal Toxicity
- (2012) Suzanne R. Hayman et al. Current Oncology Reports
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Frontline treatment of localized osteosarcoma without methotrexate
- (2011) Najat C. Daw et al. CANCER
- Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer
- (2011) D. Hompes et al. EJSO
- A Review on Bevacizumab and Surgical Wound Healing
- (2009) Chad R. Gordon et al. ANNALS OF PLASTIC SURGERY
- Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds
- (2009) I. Kumar et al. BRITISH JOURNAL OF SURGERY
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
- (2008) Paul A. Meyers et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More